NASDAQ · Biotechnology

Jounce Therapeutics, Inc. (JNCE) Stock

$1.88 +0.00% NASDAQ: JNCE Healthcare

Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments.

Valuation

MetricValue
Price$1.88
Market Cap$98.95M
P/E Ratio-1.90
P/B Ratio0.53
P/S Ratio1.21
EPS (TTM)$-0.99
52-Week High$5.37
52-Week Low$0.58
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-25.03%
ROA-23.96%
ROCE-27.64%
Gross Margin100.00%
Operating Margin-63.71%
Net Margin-62.10%
Debt/Equity0.05
Current Ratio8.37

Annual Financials (USD)

Metric20182019202020212022
Revenue$65.0M$148.0M$62.0M$27.0M$82.0M
Operating Profit$-31.0M$53.0M$-45.0M$-91.0M$-52.0M
Net Profit$-27.0M$57.0M$-44.0M$-91.0M$-51.0M
EPS$-0.84$1.66$-1.24$-1.82$-0.99
Op Margin-48.0%35.7%-72.4%-338.4%-63.7%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$214.0M$206.0M$244.0M$253.0M$213.0M
Total Liabilities$110.0M$31.0M$33.0M$29.0M$29.0M
Cash$48.0M$53.0M$147.0M$96.0M$151.0M
Borrowings$0$20.0M$17.0M$14.0M$10.0M

Latest News

TowneBank Q2 Earnings, Revenue Rise MT Newswires · Jul 23, 2026 Renault says sales stalled in first half AFP · Jul 23, 2026 Should You Buy Amazon and Meta Platforms Stocks Before July 29? Motley Fool · Jul 23, 2026 argenx Q2 Profit, Total Operating Income Rise MT Newswires · Jul 23, 2026 STMicroelectronics Q2 Non-GAAP Earnings, Revenue Rise MT Newswires · Jul 23, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-64.0M$-30.0M$-28.0M$-83.0M$-29.0M
Investing Cash Flow$85.0M$30.0M$51.0M$-61.0M$83.0M
Financing Cash Flow$2.0M$4.0M$126.0M$92.0M$0
Net Cash Flow$24.0M$5.0M$94.0M$-52.0M$55.0M
Free Cash Flow$-65.0M$-31.0M$-28.0M$-84.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.09
EV / EBITDA0.83
FCF Yield-30.11%
Quick Ratio8.37
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AADIAadi Bioscience, Inc. $2.05 -2.38% -1.49 $94.89M 0.00%
BLIBerkeley Lights, Inc. $1.20 -5.88% -0.85 $86.61M 0.00%
CYTCyteir Therapeutics, Inc. $3.02 -2.27% -2.42 $108.71M 0.00%
DBTXDecibel Therapeutics, Inc. $4.91 -0.81% -1.95 $123.37M 0.00%
HLVXHilleVax, Inc. $2.09 -0.48% -9.09 $104.76M 0.00%

About Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors. The company is also progressing JTX-8064, an antibody designed to target leukocyte immunoglobulin like receptor B2 (LILRB2), a cell surface receptor found on macrophages. Additionally, JTX-1484 is under development, focusing on myeloid targets. Completing its innovative portfolio is JTX-1811, an anti-CCR8 monoclonal antibody precisely engineered to selectively reduce the presence of intra-tumoral T regulatory cells within the tumor's microenvironment. Jounce Therapeutics, Inc. was founded in 2012 and maintains its primary operational base in Cambridge, Massachusetts.

Jounce Therapeutics, Inc. is headquartered in US.

Jounce Therapeutics, Inc. (JNCE) stock trades at $1.88 with a market capitalization of $98.95M. The stock is valued at a price-to-earnings (P/E) ratio of -1.90, price-to-book of 0.53, price-to-sales of 1.21. Over the past 52 weeks the stock has ranged between $0.58 and $5.37, and currently trades 65.0% below its 52-week high.

On profitability, Jounce Therapeutics, Inc. generates a return on equity (ROE) of -25.03%, return on capital employed of -27.64%, an operating margin of -63.71%, a net profit margin of -62.10%.

Official website: jouncetx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides